These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 4690029)

  • 1. Experimental evaluation of in situ oncocide for primary tumor therapy: comparison of tumor-specific immunity after complete excision, cryonecrosis and ligation.
    Neel HB; Ketcham AS; Hammond WG
    Laryngoscope; 1973 Mar; 83(3):376-87. PubMed ID: 4690029
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of tumor immunity after complete excision, cryonecrosis, and in the presence of persistent tumor.
    Neel HB; Ketcham AS; Hammond WG
    Surg Forum; 1970; 21():120-2. PubMed ID: 5514704
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapeutic effect of tumor necrosis in situ.
    Neel HB; Ritts RE
    Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol; 1977; 84(2):285-90. PubMed ID: 898501
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunity to a TA3 tumor subline that grows in allogeneic hosts elicited by strain-specific TA3 tumor cells.
    Lippman MM; Venditti JM; Kline I; Elam DL
    Cancer Res; 1973 Apr; 33(4):679-84. PubMed ID: 4696468
    [No Abstract]   [Full Text] [Related]  

  • 5. Cryolumpectomy for carcinoma of the breast.
    Rand RW; Rand RP; Eggerding F; DenBesten L; King W
    Surg Gynecol Obstet; 1987 Nov; 165(5):392-6. PubMed ID: 2823400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of serial transplantation on the immunological-clinical correlates of BALB/cfC3H mouse mammary tumors.
    Hager JC; Miller FR; Heppner GH
    Cancer Res; 1978 Aug; 38(8):2492-500. PubMed ID: 667845
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune status of autochthonous and adoptively protected mice toward spontaneous and chemically induced tumors.
    Basombrío MA; Prehn RT
    Cancer Res; 1972 Nov; 32(11):2545-50. PubMed ID: 5082598
    [No Abstract]   [Full Text] [Related]  

  • 8. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
    Giovarelli M; Musiani P; Garotta G; Ebner R; Di Carlo E; Kim Y; Cappello P; Rigamonti L; Bernabei P; Novelli F; Modesti A; Coletti A; Ferrie AK; Lollini PL; Ruben S; Salcedo T; Forni G
    J Immunol; 1999 Nov; 163(9):4886-93. PubMed ID: 10528190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific transplantation immunity after cryosurgery.
    Myers RS; Hammond WG; Ketcham AS
    J Surg Oncol; 1969; 1(3):241-6. PubMed ID: 5406367
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of parabiosis on tumour growth in tumour bearing animals.
    Postuma HS
    Arch Chir Neerl; 1973; 25(3):269-82. PubMed ID: 4355262
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergism between host anti-tumor immunity and combined modality therapy against murine breast cancer.
    Stolfi RL; Fugmann RA; Stolfi LM; Martin DS
    Int J Cancer; 1974 Mar; 13(3):389-403. PubMed ID: 4822108
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune response to inactivated syngeneic mammary adenocarcinoma cells. II. Parameters of immunogenicity in DBA/2 mice.
    DeLustro F; Haskill JS
    J Natl Cancer Inst; 1980 Jan; 64(1):131-7. PubMed ID: 6928038
    [No Abstract]   [Full Text] [Related]  

  • 13. Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor.
    Sabel MS; Arora A; Su G; Chang AE
    Cryobiology; 2006 Dec; 53(3):360-6. PubMed ID: 16973145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor immunity induced by hybrid murine tumor cells: requirements for optimal immunization.
    McCune CS; O'Donnell RW; Horan PK; Budd HS; Spennacchio JL; Chuang C; Henshaw EC
    J Natl Cancer Inst; 1982 Sep; 69(3):647-52. PubMed ID: 6955557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.
    Carr-Brendel V; Markovic D; Ferrer K; Smith M; Taylor-Papadimitriou J; Cohen EP
    Cancer Res; 2000 May; 60(9):2435-43. PubMed ID: 10811121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstration of tumor-specific immunity against antigens unrelated to the mammary tumor virus in spontaneous mammary adenocarcinomas.
    Morton DL; Miller GF; Wood DA
    J Natl Cancer Inst; 1969 Feb; 42(2):289-301. PubMed ID: 4303881
    [No Abstract]   [Full Text] [Related]  

  • 17. Immune response to inactivated syngeneic mammary adenocarcinoma cells. I. Role and regulation of antibody synthesis in DBA/2 mice.
    DeLustro F; Haskill JS
    J Natl Cancer Inst; 1980 Jan; 64(1):125-30. PubMed ID: 6928037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of immunization with subcellular fractions on tumor growth in C3H/HEN mice.
    Minton JP
    Surg Forum; 1968; 19():91-3. PubMed ID: 5718434
    [No Abstract]   [Full Text] [Related]  

  • 19. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma.
    Cavallo F; Di Pierro F; Giovarelli M; Gulino A; Vacca A; Stoppacciaro A; Forni M; Modesti A; Forni G
    Cancer Res; 1993 Nov; 53(21):5067-70. PubMed ID: 8221636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to a transplantable rat mammary tumor (DMBA 8BT) after pre-treatment with syngeneic fetal cells.
    Cocuzzi E; Kellen JA
    Res Commun Chem Pathol Pharmacol; 1978 May; 20(2):405-8. PubMed ID: 674823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.